Low C reactive protein-alleles in hepatocyte nuclear factor 1A are associated with an increased risk of cardiovascular disease: a Meta-analysis.
肝細胞核因子1A中的低C反應蛋白等位基因與心血管疾病風險增加相關:一項Meta分析。
J Clin Endocrinol Metab 2024-08-30
Tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase 3 randomized controlled trials.
Tirzepatide 在管理 2 型糖尿病方面優於長效胰島素:三項第三期隨機對照試驗的 meta-analysis。
Int J Obes (Lond) 2024-08-29
Manipulation of Post-Prandial Hyperglycaemia in Type 2 Diabetes: An Update for Practitioners.
2 型糖尿病餐後高血糖的調控:給從業者的最新更新。
Diabetes Metab Syndr Obes 2024-08-29
Exploring a Synergistic Approach: Dual GLP-1 Agonist Combined with Degludec Basal Insulin for Early Type 1 Diabetes Treatment and its Impact on Albumin-Insulin Producing Cells Expression.
探索協同療法:雙重 GLP-1 激動劑結合 Degludec 基礎胰島素對早期 1 型糖尿病治療及其對白蛋白-胰島素產生細胞表達的影響。
Adv Pharm Bull 2024-08-29
The effectiveness of 0.5 mg and 1mg of semaglutide in patients with type two diabetes and predictors of response: a retrospective cohort study.
0.5 mg 和 1 mg semaglutide 在二型糖尿病患者中的療效及反應預測因子:一項回顧性隊列研究。
Front Endocrinol (Lausanne) 2024-08-29
Caveolae with GLP-1 and NMDA Receptors as Crossfire Points for the Innovative Treatment of Cognitive Dysfunction Associated with Neurodegenerative Diseases.
以 GLP-1 和 NMDA 受體為交火點的洞穴小體:創新治療與神經退行性疾病相關的認知功能障礙。
Molecules 2024-08-29
The Synthesis of SNAC Phenolate Salts and the Effect on Oral Bioavailability of Semaglutide.
SNAC 酚酸鹽的合成及其對 Semaglutide 口服生物利用度的影響。
Molecules 2024-08-29